On the heels of some important “firsts” this past year, xenotransplantation — grafting animal organs into humans — is on the cusp of crossing over into new
Tag - Breakthrough22
Mark Cuban’s drug company started with an ambitious premise: to circumvent middlemen to offer cheaper costs to patients. To do so, the company has had to
Were the oily rodents impressive enough? More amazing than the family tree of tumors? Than the tiny, autonomous, faux “cells” that went around sucking up water
Califf admits controversy over FDA’s Alzheimer’s drug decision impacted experts’ trust in the agency
NEW YORK — Robert Califf, the new head of the Food and Drug Administration, admitted Thursday that the agency’s controversial approval of the Alzheimer’s drug
NEW YORK — Earlier this month, the U.S. Patent and Trademark Office ruled that CRISPR patents key to developing human therapies belong to the Broad Institute
